Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

Patients with multiple myeloma progressing on current therapies have limited treatment options. Pomalidomide (CC4047), an immunomodulatory drug, has significant activity in relapsed myeloma and previous studies suggest activity in lenalidomide refractory disease. To better define its efficacy in thi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Lacy, MQ, Hayman, SR, Gertz, MA, Short, KD, Dispenzieri, A, Kumar, S, Greipp, PR, Lust, JA, Russell, SJ, Dingli, D, Zeldenrust, S, Fonseca, R, Bergsagel, PL, Roy, V, Mikhael, JR, Stewart, AK, Laumann, K, Allred, JB, Mandrekar, SJ, Rajkumar, SV, Buadi, F
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2978257/
https://ncbi.nlm.nih.gov/pubmed/20827286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2010.190
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars